MNPRHealthcare · BiotechnologyMNPR Stock Forecast: Monopar Therapeutics, Inc. Price Predictions for 2026-2027
The 13 Wall Street analysts covering Monopar Therapeutics, Inc. hold a median 12-month price target of $117 — +4.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 1 Aug 2026 — in the upper half.
MNPR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Monopar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (85): The shares have been drifting up relative to others.
Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Monopar Therapeutics, Inc. — and when they’d sell — is the membership.
MNPR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MNPR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +4.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 July 2026 | HC Wainwright & Co. | Maintains | Buy | $105 → $125 |
| 30 June 2026 | BTIG | Maintains | Buy | — |
| 30 June 2026 | BTIG | Maintains | Buy | $104 → $117 |
| 29 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $105 |
| 30 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 23 Feb 2026 | BTIG | Reiterates | Buy | — |
| 2 Feb 2026 | BTIG | Reiterates | Buy | — |
| 29 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 14 Jan 2026 | BTIG | Reiterates | Buy | — |
| 9 Jan 2026 | Morgan Stanley | Initiates | Overweight | — |
| 14 Nov 2025 | Raymond James | Downgrade | Outperform | — |
| 13 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 10 Nov 2025 | Leerink Partners | Initiates | Outperform | — |
| 9 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Oct 2025 | Barclays | Initiates | Overweight | — |
| 6 Oct 2025 | Raymond James | Maintains | Strong Buy | — |
| 2 Oct 2025 | Oppenheimer | Maintains | Outperform | — |
| 29 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 25 Sept 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MNPR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Monopar Therapeutics, Inc. (MNPR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −58.5×
- Price / sales
- —
- Price / book
- 5.4×
- EV / EBITDA
- −35.2×
Cheaper than 98% of US stocks
Cheaper than 20% of US stocks
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −15.9%
- Return on assets
- −12.1%
- Dividend yield
- —
Higher than 33% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MNPR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MNPR appears on the weeks it earns a place.
Frequently asked questions about MNPR stock
What is the MNPR stock price forecast for 2026-2027?
The 13 Wall Street analysts covering Monopar Therapeutics, Inc. have a median 12-month price target of $117, with estimates ranging from $100 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MNPR stock a buy right now?
Of the 13 analysts covering Monopar Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monopar Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MNPR?
As at 1 Aug 2026, Monopar Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).
Will MNPR stock go up?
No one can know that. What the data says: the median 12-month target from 13 analysts implies +4.8% from the last close, and Ticker Nerd's factor model ranks Monopar Therapeutics, Inc. 65 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MNPR stock forecast for 2030?
No analyst covering Monopar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $130 over the next 12 months.
How has MNPR stock performed over the past year?
Monopar Therapeutics, Inc. returned +174.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Monopar Therapeutics, Inc. do?
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for oncology and a therapy for Wilson disease.
About Monopar Therapeutics, Inc.
Monopar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing radiopharmaceuticals for oncology and a therapy for Wilson disease. Its current portfolio centers on advanced cancer programs built around the MNPR-101 platform, including imaging and therapeutic candidates designed to target solid tumors that express uPAR. The company is also advancing ALXN1840, a late-stage investigational medicine for Wilson disease, a rare genetic disorder that affects copper metabolism. Monopar Therapeutics Inc. develops its pipeline through internal research and licensing of late preclinical and clinical-stage assets, concentrating on areas with significant unmet medical need. Based in Wilmette, Illinois, the company operates as a specialized drug development business within biotechnology, with a focus on precision oncology and rare disease treatment.
CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. · 22 employees · United States · https://www.monopartx.com